NCT05257083 2026-03-17
CARTITUDE-6
European Myeloma Network B.V.
Phase 3 Active not recruiting
Clinical Trials
24 trialsNCT03937635 2026-03-02
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04566328 2026-03-02
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT05243797 2026-02-17
MajesTEC-4
European Myeloma Network B.V.
Phase 3 Recruiting
NCT03710603 2026-02-10
Perseus
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT06932562 2026-01-23
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
European Myeloma Network B.V.
Phase 3 Recruiting
NCT05890352 2025-10-20
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
SWOG Cancer Research Network
Phase 2 Recruiting
NCT04071457 2025-09-15
DRAMMATIC
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT01863550 2025-09-08
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT05123131 2025-07-08
Isa-RVD
Cancer Trials Ireland
Phase 2 Active not recruiting
NCT05561387 2025-06-04
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
SWOG Cancer Research Network
Phase 3 Recruiting
NCT01415752 2025-04-08
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04934475 2024-11-07
MIDAS
Intergroupe Francophone du Myelome
Phase 3 Active not recruiting
NCT06189833 2024-04-23
TAURUS
European Myeloma Network B.V.
Phase 2 Recruiting
NCT00305812 2023-08-04
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
Canadian Cancer Trials Group
Phase 2 Completed
NCT01216683 2023-06-29
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02219178 2020-07-17
Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Cancer Trials Ireland
Phase 2 Completed
NCT01098656 2018-07-09
Lenalidomide Maintenance Post-debulking in Advanced CTCL
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT01460420 2017-07-06
EMN-alloRIC
European Myeloma Network B.V.
Phase 1/2 Completed
NCT00064038 2015-03-25
S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma
SWOG Cancer Research Network
Phase 3 Completed
NCT01055301 2015-03-06
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00847639 2014-04-04
07-REV
Center for International Blood and Marrow Transplant Research
Phase 2 Completed
NCT01556477 2012-03-16
The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).
Nordic MDS Group
Phase 2 Unknown
NCT00628238 2010-09-10
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia Research Consortium
Phase 2 Unknown